Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obatoclax + Docetaxel in Relapsed/Refractory NSCLC
NCT00405951Phase 2Completed
- Sponsor
- Gemin X Pharmaceuticals
- Start
- Oct 2006
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obatoclax in non-small cell lung cancer (NSCLC), sponsored by Gemin X Pharmaceuticals. Primary endpoint: Overall Response Rate at 18 months. Started Oct 2006; status: completed.
02
Drugs
obatoclax
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00405951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00405951.